---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027933"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:39:04.197916+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics appoints Alfonso Quintás-Cardama as CMO; Sam Agresta departs Sept 11, 2023

## Summary
- Samuel Agresta steps down as CMO effective September 11, 2023; will consult through early January 2024.
- Alfonso Quintás-Cardama appointed CMO effective September 11, 2023; previously CMO at TCR2 Therapeutics.
- Dr. Quintás-Cardama helped develop Kymriah (tisagenlecleucel) at Novartis and led cell therapy clinical dev at GSK.
- He was a faculty member at MD Anderson Cancer Center (2009-2014) developing targeted agents for myeloid malignancies.

## SEC filing metadata
- accession: 0001628280-23-027933
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828023027933/0001628280-23-027933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828023027933/fhtx-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027933
- JSON: https://secwatch.observer/filing/0001628280-23-027933.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.